Dr Reddy's Laboratories Ltd has announced on Monday that it has completed the acquisition of 100 per cent of Betapharm Group, the fourth largest generic pharmaceuticals company based in Germany, for a total enterprise value of {euro} 480 million in cash. In a press release here, Dr Reddy's Chief Operating Officer, Mr Satish Reddy, said, "We have successfully completed the acquisition of Betapharm. The strategic investment in Betapharm is a step forward towards realising Dr Reddy's strategic intention of building a global generics business with strategic presence in all key markets."
